Hanmi Pharm (KRX:128940) posted first-quarter net income attributable to shareholders of the parent company of 42.6 billion won, down 22.5% from 55 billion won a year earlier, the pharmaceutical company said in a Tuesday regulatory filing with Korea Exchange.
The company's sales fell 3.2% year over year to 390.9 billion won from 403.7 billion won.
Shares of Hanmi Pharm jumped nearly 9% at market close on Wednesday, April 30.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。